SYGNIS Pharma / SYGNIS licenses amplification buffer to QIAGEN . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
- Agreement follows a global licence agreement signed with QIAGEN in 2012.
- First non-exclusive licence agreement for a new amplification buffer developed by Professor Salas at the CSIC laboratory.
Madrid/Heidelberg, 16 May 2013 - Spanish-German biotech company SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard segment of the German Stock Exchange) has signed a licence agreement for the distribution of a new amplification buffer with QIAGEN, the global leader in sample and assays technologies. This is the second agreement with QIAGEN within 9 months and the first licence agreement for the amplification buffer technology developed by the team led by renowned Professor Margarita Salas at the CSIC laboratory.
The recently granted licence covers a new amplification buffer, a tool used in isothermal amplification, providing superior reaction performance.
"With the new agreement, SYGNIS adds a global reference in the sector in the fields of DNA amplification research and commercial markets. This newly signed agreement shows that SYGNIS is making progress in the commercialization of core technologies and products designed for the DNA sequencing and amplification market. It strengthens the network of relationships we maintain with life science and diagnostics companies in the DNA amplification industry," SYGNIS' CEO Pilar de la Huerta commented.
Background
In July 2012, through X-POL, SYGNIS reached an exclusive global licence agreement with QIAGEN for the distribution of the polymerase QualiPhi®.
QualiIPhi® is an upgraded version of phi 29 DNA polymerase. Compared to similar polymerase proteins on the market, the new one exhibits enhanced properties. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, among other applications.
Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are basic in research involving analysis and modification of DNA from any species.
About SYGNIS Pharma AG: www.sygnis.de (http://www.sygnis.de/)
After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi® and is currently developing other products in the field of Next Generation Sequencing.//
For further information please contact:
| SYGNIS Pharma AG | |||
| Pilar de la Huerta CEO/CFO | |||
| Tel: +34-918063089 | |||
| Email: pdelahuerta@sygnis.es (mailto:pdelahuerta@sygnis.es) |
# # # Disclaimer:
Some statements included in this press release, relating neither to proven financial results nor to other historical data, should be viewed as forward-looking, i.e. not definitive. Such statements are mainly predictions of future results, trends, plans or goals. They should not be considered to be total guarantees since given their very nature, they are subject to known and unknown risks, as well as to aspects beyond human control, and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise said statements in light of new information or future results or for any other reason. # # #
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: SYGNIS Pharma via Thomson Reuters ONE
--- End of Message ---
SYGNIS Pharma
Im Neuenheimer Feld 515 Heidelberg Germany
